Thomas Duell Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

1/2022	Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
1/2021	Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
5/2017	Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients.
1/2017	Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer.
5/2016	Genetic changes of non-small cell lung cancer under neoadjuvant therapy.
1/2015	Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial.
1/2009	Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer.
3/2008	Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Duell Research Topics

Disease

8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 03/2008
5	Neoplasms (Cancer) 05/2019 - 12/2008
5	Lung Neoplasms (Lung Cancer) 02/2019 - 05/2010
1	Disease Progression 01/2022
1	Pneumonia (Pneumonitis) 01/2021
1	Mesothelioma 05/2019
1	Malignant Mesothelioma 05/2019
1	Type 2 Diabetes Mellitus (MODY) 05/2017
1	Adenocarcinoma of Lung 01/2017
1	Pleural Diseases 06/2011
1	Lung Diseases (Lung Disease) 05/2010
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2008
1	Brain Neoplasms (Brain Tumor) 03/2008
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2006
1	Refractory Anemia with Excess of Blasts (RAEM) 01/2006

Drug/Important Bio-Agent (IBA)

4	Peptides (Polypeptides)IBA 01/2015 - 12/2008
3	big gastrinIBA 05/2010 - 12/2008
3	Phosphopyruvate Hydratase (Enolase)IBA 05/2010 - 12/2008
3	antigen CYFRA21.1IBA 05/2010 - 12/2008
3	Carcinoembryonic AntigenIBA 05/2010 - 12/2008
3	pro-gastrin-releasing peptide (31-98)IBA 05/2010 - 12/2008
2	Tyrosine Kinase InhibitorsIBA 01/2017 - 03/2008
2	Biomarkers (Surrogate Marker)IBA 05/2010 - 12/2008
2	Nucleosomes (Nucleosome)IBA 01/2009 - 12/2008
2	Keratin-19 (Keratin 19)IBA 01/2009 - 12/2008
1	Immune Checkpoint InhibitorsIBA 01/2022
1	durvalumabIBA 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2019
1	Cisplatin (Platino)FDA LinkGeneric 05/2019
1	Pharmaceutical PreparationsIBA 05/2017
1	Metformin (Glucophage)FDA LinkGeneric 05/2017
1	Biological ProductsIBA 05/2017
1	Environmental CarcinogensIBA 01/2017
1	Formaldehyde (Formol)FDA Link 05/2016
1	ParaffinIBA 05/2016
1	Interleukin-2 (IL2)IBA 01/2015
1	SuspensionsIBA 01/2015
1	Monoclonal AntibodiesIBA 01/2015
1	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 01/2015
1	AsbestosIBA 06/2011
1	Thymidine KinaseIBA 05/2010
1	Tumor Biomarkers (Tumor Markers)IBA 05/2010
1	Keratins (Keratin)IBA 05/2010
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2008
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2006

Therapy/Procedure

5	Therapeutics 05/2017 - 01/2006
4	Drug Therapy (Chemotherapy) 05/2017 - 12/2008
3	Chemoradiotherapy 01/2022 - 01/2015
1	Aftercare (After-Treatment) 02/2019
1	Neoadjuvant Therapy 05/2016